The unanticipated complexities of personalised medicine in the clinic
- In: MINI SYMPOSIUM: PERSONALIZED MEDICINE IN THE CLINIC: READY FOR PRIMETIME? on Tuesday, 15 April 2014, 09:00-10:00
- At: PSWC, Melbourne (Australia) (2014)
- Type: Presentation
- By: WARD, Robyn (UNSW, Prince of Wales Clinical School, Randwick nsw, Australia)
Molecular markers are used to select individuals with a differential benefit to specific therapies. In the case of high cost therapies such as anti-EGFR antibodies, a predictive biomarker represents an opportunity to limit therapy to the subgroup of patients most likely to benefit, thus improving cost-effectiveness of the drug. These and other.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.